Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12–13

HOS-112075 · Präparat HOS-093615

12 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration Nevirapine 200 mg twice daily Nevirapine AUC: ↑26% (↑17% ↑36%) Co-administration of nevirapine (atazanavir 400 mg once daily Nevirapine Cmax: ↑21% (↑11% ↑32%) and REYATAZ is not with ritonavir 100 mg once daily) Nevirapine Cmin: ↑35% (↑25% ↑47%) recommended (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nevirapine (HOS-088064) ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-112076 · Präparat HOS-093615

Study conducted in HIV-infected Atazanavir AUC: ↓19% (↓35% ↑2%)* patients. Atazanavir Cmax: ↔2% (↓15% ↑24%)* Atazanavir Cmin: ↓59% (↓73% ↓40%)*

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-112077 · Präparat HOS-093615

*When compared to REYATAZ 300 mg and ritonavir 100 mg without nevirapine. This decrease in atazanavir Cmin might negatively impact the efficacy of atazanavir. The mechanism of nevirapine/atazanavir interaction is CYP3A4 induction. Integrase Inhibitors Raltegravir 400 mg twice daily Raltegravir AUC: ↑41% No dose adjustment required for (atazanavir/ritonavir) Raltegravir Cmax: ↑24% raltegravir. Raltegravir C12hr: ↑77%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): raltegravir (HOS-086187) nevirapine (HOS-088064) ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-112078 · Präparat HOS-093615

The mechanism is UGT1A1 inhibition. ANTIBIOTICS Clarithromycin 500 mg twice Clarithromycin AUC: ↑94% (↑75% No recommendation regarding dose daily ↑116%) reduction can be made; therefore, (atazanavir 400 mg once daily) Clarithromycin Cmax: ↑50% (↑32% ↑71%) caution should be exercised if Clarithromycin Cmin: ↑160% (↑135% REYATAZ is co-administered with ↑188%) clarithromycin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-112079 · Präparat HOS-093615

14-OH clarithromycin 14-OH clarithromycin AUC: ↓70% (↓74% ↓66%) 14-OH clarithromycin Cmax: ↓72% (↓76% ↓67%) 14-OH clarithromycin Cmin: ↓62% (↓66% ↓58%)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-112080 · Präparat HOS-093615

Atazanavir AUC: ↑28% (↑16% ↑43%) Atazanavir Cmax: ↔6% (↓7% ↑20%) Atazanavir Cmin: ↑91% (↑66% ↑121%)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-112081 · Präparat HOS-093615

A dose reduction of clarithromycin may result in subtherapeutic concentrations of 14-OH clarithromycin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13

HOS-112082 · Präparat HOS-093615

The mechanism of the clarithromycin/atazanavir interaction is CYP3A4 inhibition. ANTIFUNGALS Ketoconazole 200 mg once daily No significant effect on atazanavir Ketoconazole and itraconazole (atazanavir 400 mg once daily) concentrations was observed. should be used cautiously with Itraconazole Itraconazole, like ketoconazole, is a strong REYATAZ/ritonavir, high doses of inhibitor as well as a substrate of CYP3A4. ketoconazole and itraconazole (> 200 mg/day) are not Based on data obtained with other boosted recommended. PIs and ketoconazole, where ketoconazole AUC showed a 3-fold increase, REYATAZ/ritonavir is expected to increase ketoconazole or itraconazole concentrations.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13–14

HOS-112083 · Präparat HOS-093615

13 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration Voriconazole 200 mg twice daily Voriconazole AUC: ↓33% (↓42% ↓22%) Co-administration of voriconazole (atazanavir 300 mg/ritonavir Voriconazole Cmax: ↓10% (↓22% ↓4%) and REYATAZ with ritonavir is 100 mg once daily) Voriconazole Cmin: ↓39% (↓49% ↓28%) not recommended unless an assessment of the benefit/risk to the Subjects with at least one Atazanavir AUC: ↓12% (↓18% ↓5%) patient justifies the use of functional CYP2C19 allele. Atazanavir Cmax: ↓13% (↓20% ↓4%) voriconazole (see section 4.4). Atazanavir Cmin: ↓20% (↓28% ↓10%) At the time voriconazole treatment Ritonavir AUC: ↓12% (↓17% ↓7%) is required, a patient's CYP2C19 Ritonavir Cmax: ↓9% (↓17% ↔0%) genotype should be performed if Ritonavir Cmin: ↓25% (↓35% ↓14%) feasible.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): voriconazole (HOS-084524) ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 14

HOS-112084 · Präparat HOS-093615

In the majority of patients with at least one Therefore if the combination is functional CYP2C19 allele, a reduction in unavoidable, the following both voriconazole and atazanavir recommendations are made exposures are expected. according to the CYP2C19 status: Voriconazole 50 mg twice daily Voriconazole AUC: ↑561% (↑451% - in patients with at least one (atazanavir 300 mg/ritonavir ↑699%) functional CYP2C19 allele, 100 mg once daily) Voriconazole Cmax: ↑438% (↑355% close clinical monitoring for ↑539%) a loss of both voriconazole Subjects without a functional Voriconazole Cmin: ↑765% (↑571% (clinical signs) and CYP2C19 allele. ↑1,020%) atazanavir (virologic response) efficacy is Atazanavir AUC: ↓20% (↓35% ↓3%) recommended. Atazanavir Cmax: ↓19% (↓34% ↔0.2%) Atazanavir Cmin: ↓31% (↓46% ↓13%) - in patients without a functional CYP2C19 allele, Ritonavir AUC: ↓11% (↓20% ↓1%) close clinical and laboratory Ritonavir Cmax: ↓11% (↓24% ↑4%) monitoring of voriconazole- Ritonavir Cmin: ↓19% (↓35% ↑1%) associated adverse events is recommended. In a small number of patients without a functional CYP2C19 allele, significantly If genotyping is not feasible, full increased voriconazole exposures are monitoring of safety and efficacy expected. should be performed. Fluconazole 200 mg once daily Atazanavir and fluconazole concentrations No dosage adjustments are needed (atazanavir 300 mg and ritonavir were not significantly modified when for fluconazole and REYATAZ. 100 mg once daily) REYATAZ/ritonavir was co-administered with fluconazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): voriconazole (HOS-084524) fluconazole (HOS-087945) ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 14–15

HOS-112085 · Präparat HOS-093615

14 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration ANTIMYCOBACTERIAL Rifabutin 150 mg twice weekly Rifabutin AUC: ↑48% (↑19% ↑84%)** When given with REYATAZ, the (atazanavir 300 mg and ritonavir Rifabutin Cmax: ↑149% (↑103% ↑206%)** recommended dose of rifabutin is 100 mg once daily) Rifabutin Cmin: ↑40% (↑5% ↑87%)** 150 mg 3 times per week on set days (for example Monday- 25-O-desacetyl-rifabutin AUC: ↑990% Wednesday-Friday). Increased (↑714% ↑1 361%)** monitoring for rifabutin-associated 25-O-desacetyl-rifabutin Cmax: ↑677% adverse reactions including (↑513% ↑883%)** neutropenia and uveitis is warranted 25-O-desacetyl-rifabutin Cmin: ↑1 045% due to an expected increase in (↑715% ↑1 510%)** exposure to rifabutin. Further dosage reduction of rifabutin to **When compared to rifabutin 150 mg 150 mg twice weekly on set days is once daily alone. Total rifabutin and recommended for patients in whom 25-O-desacetyl-rifabutin AUC: ↑119% the 150 mg dose 3 times per week (↑78% ↑169%). is not tolerated. It should be kept in mind that the twice weekly dosage In previous studies, the pharmacokinetics of 150 mg may not provide an of atazanavir was not altered by rifabutin. optimal exposure to rifabutin thus leading to a risk of rifamycin resistance and a treatment failure. No dose adjustment is needed for REYATAZ. Rifampicin Rifampicin is a strong CYP3A4 inducer The combination of rifampicin and and has been shown to cause a 72% REYATAZ is contraindicated decrease in atazanavir AUC which can (see section 4.3). result in virological failure and resistance development. During attempts to overcome the decreased exposure by increasing the dose of REYATAZ or other protease inhibitors with ritonavir, a high frequency of liver reactions was seen. ANTIPSYCHOTICS Quetiapine Due to CYP3A4 inhibition by REYATAZ, Co-administration of quetiapine concentrations of quetiapine are expected with REYATAZ is contraindicated to increase. as REYATAZ may increase quetiapine-related toxicity. Increased plasma concentrations of quetiapine may lead to coma (see section 4.3). Lurasidone REYATAZ is expected to increase plasma Co-administration of lurasidone levels of lurasidone due to CYP3A4 with REYATAZ is contraindicated inhibition. as this may increase lurasidone- related toxicity (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) protease (HOS-085623) rifabutin (HOS-086262) lead (HOS-085592) ritonavir (HOS-084521) lurasidone (HOS-086148)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 15–16

HOS-112086 · Präparat HOS-093615

15 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration ACID REDUCING AGENTS H2-Receptor antagonists Without Tenofovir In HIV-infected patients with atazanavir/ritonavir at the recommended For patients not taking tenofovir, dose 300/100 mg once daily if REYATAZ 300 mg/ritonavir Famotidine 20 mg twice daily Atazanavir AUC: ↓18% (↓25% ↑1%) 100 mg and H2-receptor antagonists Atazanavir Cmax: ↓20% (↓32% ↓7%) are co-administered, a dose Atazanavir Cmin: ↔1% (↓16% ↑18%) equivalent to famotidine 20 mg twice daily should not be exceeded. Famotidine 40 mg twice daily Atazanavir AUC: ↓23% (↓32% ↓14%) If a higher dose of an H2-receptor Atazanavir Cmax: ↓23% (↓33% ↓12%) antagonist is required (e.g., Atazanavir Cmin: ↓20% (↓31% ↓8%) famotidine 40 mg twice daily or In healthy volunteers with atazanavir/ritonavir at an increased dose equivalent) an increase of the of 400/100 mg once daily REYATAZ/ritonavir dose from Famotidine 40 mg twice daily Atazanavir AUC: ↔3% (↓14% ↑22%) 300/100 mg to 400/100 mg can be Atazanavir Cmax: ↔2% (↓13% ↑8%) considered. Atazanavir Cmin: ↓14% (↓32% ↑8%) With Tenofovir disoproxil fumarate 300 mg once daily (equivalent to 245 mg tenofovir disoproxil) In HIV-infected patients with atazanavir/ritonavir at the recommended dose For patients who are taking of 300/100 mg once daily tenofovir disoproxil fumarate, if Famotidine 20 mg twice daily Atazanavir AUC: ↓21% (↓34% ↓4%)* REYATAZ/ritonavir with both Atazanavir Cmax: ↓21% (↓36% ↓4%)* tenofovir disoproxil fumarate and Atazanavir Cmin: ↓19% (↓37% ↑5%)* an H2-receptor antagonist are co- administered, a dose increase of Famotidine 40 mg twice daily Atazanavir AUC: ↓24% (↓36% ↓11%)* REYATAZ to 400 mg with 100 mg Atazanavir Cmax: ↓23% (↓36% ↓8%)* of ritonavir is recommended. A Atazanavir Cmin: ↓25% (↓47% ↑7%)* dose equivalent to famotidine In HIV-infected patients with atazanavir/ritonavir at an increased dose 40 mg twice daily should not be of 400/100 mg once daily exceeded. Famotidine 20 mg twice daily Atazanavir AUC: ↑18% (↑6.5% ↑30%)* Atazanavir Cmax: ↑18% (↑6.7% ↑31%)* Atazanavir Cmin: ↑24% (↑10% ↑39%)* Famotidine 40 mg twice daily Atazanavir AUC: ↔2.3% (↓13% ↑10%)* Atazanavir Cmax: ↔5% (↓17% ↑8.4%)* Atazanavir Cmin: ↔1.3% (↓10% ↑15)* *When compared to atazanavir 300 mg once daily with ritonavir 100 mg once daily and tenofovir disoproxil fumarate 300 mg all as a single dose with food. When compared to atazanavir 300 mg with ritonavir 100 mg without tenofovir disoproxil fumarate, atazanavir concentrations are expected to be additionally decreased by about 20%.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) famotidine (HOS-112087) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 16

HOS-112088 · Präparat HOS-093615

The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2-blockers.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 16–17

HOS-112089 · Präparat HOS-093615

16 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration Proton pump inhibitors Omeprazole 40 mg once daily Atazanavir (am): 2 hr after omeprazole Co-administration of REYATAZ (atazanavir 400 mg once daily Atazanavir AUC: ↓61% (↓65% ↓55%) with ritonavir and proton pump with ritonavir 100 mg once daily) Atazanavir Cmax: ↓66% (↓62% ↓49%) inhibitors is not recommended. If Atazanavir Cmin: ↓65% (↓71% ↓59%) the combination is judged Omeprazole 20 mg once daily Atazanavir (am): 1 hr after omeprazole unavoidable, close clinical (atazanavir 400 mg once daily Atazanavir AUC: ↓30% (↓43% ↓14%)* monitoring is recommended in with ritonavir 100 mg once daily) Atazanavir Cmax: ↓31% (↓42% ↓17%)* combination with an increase in the Atazanavir Cmin: ↓31% (↓46% ↓12%)* dose of REYATAZ to 400 mg with 100 mg of ritonavir; doses of proton *When compared to atazanavir 300 mg pump inhibitors comparable to once daily with ritonavir 100 mg once omeprazole 20 mg should not be daily. exceeded (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) omeprazole (HOS-085912)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 17

HOS-112090 · Präparat HOS-093615

The decrease in AUC, Cmax, and Cmin was not mitigated when an increased dose of REYATAZ/ritonavir (400/100 mg once daily) was temporally separated from omeprazole by 12 hours. Although not studied, similar results are expected with other proton pump inhibitors. This decrease in atazanavir exposure might negatively impact the efficacy of atazanavir. The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with proton pump inhibitors. Antacids Antacids and medicinal Reduced plasma concentrations of REYATAZ should be administered products containing buffers atazanavir may be the consequence of 2 hours before or 1 hour after increased gastric pH if antacids, including antacids or buffered medicinal buffered medicinal products, are products. administered with REYATAZ. ALPHA 1-ADRENORECEPTOR ANTAGONIST Alfuzosin Potential for increased alfuzosin Co-administration of alfuzosin with concentrations which can result in REYATAZ is contraindicated hypotension. The mechanism of (see section 4.3) interaction is CYP3A4 inhibition by REYATAZ and/or ritonavir. ANTICOAGULANTS Direct-acting oral anticoagulants (DOACs) Apixaban Potential for increased apixaban and Co-administration of apixaban or Rivaroxaban rivaroxaban concentrations which can rivaroxaban and REYATAZ with result in a higher risk of bleeding. ritonavir is not recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) rivaroxaban (HOS-086236) apixaban (HOS-112091) ritonavir (HOS-084521) omeprazole (HOS-085912)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 17

HOS-112092 · Präparat HOS-093615

The mechanism of interaction is inhibition of CYP3A4/and P-gp by REYATAZ/ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 17

HOS-112093 · Präparat HOS-093615

Ritonavir is a strong inhibitor of both CYP3A4 and P-gp.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 17

HOS-112094 · Präparat HOS-093615

REYATAZ is an inhibitor of CYP3A4. The potential inhibition of P-gp by REYATAZ is unknown and cannot be excluded.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 17–18

HOS-112095 · Präparat HOS-093615

17 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration Dabigatran Potential for increased dabigatran Co-administration of dabigatran concentrations which can result in a higher and REYATAZ with ritonavir is risk of bleeding. The mechanism of not recommended. interaction is P-gp inhibition.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dabigatran (HOS-112096) ritonavir (HOS-084521)

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 18

HOS-112097 · Präparat HOS-093615

Ritonavir is a strong P-gp inhibitor.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521)